Search

Your search keyword '"Hejl, Carine"' showing total 46 results
Start Over Author "Hejl, Carine"
46 results on '"Hejl, Carine"'

6. Long-term systemic and mucosal SARS-CoV-2 IgA response and its association with persistent smell and taste disorders.

Author

Denis, Jessica, Garnier, Annabelle, Cheutin, Laurence, Ferrier, Audrey, Timera, Hawa, Jarjaval, Fanny, Hejl, Carine, Billon-Denis, Emmanuelle, Ricard, Damien, Tournier, Jean-Nicolas, Trignol, Aurélie, and Mura, Marie

Subjects
TASTE disorders, SMELL disorders, IMMUNOGLOBULIN A, MEDICAL personnel, COVID-19
Abstract

Introduction: Current approved COVID-19 vaccines, notably mRNA and adenoviral vectored technologies, still fail to fully protect against infection and transmission of various SARS-CoV-2 variants. The mucosal immunity at the upper respiratory tract represents the first line of defense against respiratory viruses such as SARS-CoV-2 and is thus critical to develop vaccine blocking human-to-human transmission. Methods: We measured systemic and mucosal Immunoglobulin A (IgA) response in serum and saliva from 133 healthcare workers from Percy teaching military hospital following a mild infection (SARS-CoV-2 Wuhan strain, n=58) or not infected (n=75), and after SARS-CoV-2 vaccination (Vaxzevria®/Astrazeneca and/or Comirnaty®/Pfizer). Results: While serum anti-SARS-CoV-2 Spike IgA response lasted up to 16 months post-infection, IgA response in saliva had mostly fallen to baseline level at 6 months post-infection. Vaccination could reactivate the mucosal response generated by prior infection, but failed to induce a significant mucosal IgA response by itself. Early post-COVID-19 serum anti-Spike-NTD IgA titer correlated with seroneutralization titers. Interestingly, its saliva counterpart positively correlated with persistent smell and taste disorders more than one year after mild COVID-19. Discussion: As breakthrough infections have been correlated with IgA levels, other vaccine platforms inducing a better mucosal immunity are needed to control COVID-19 infection in the future. Our results encourage further studies to explore the prognosis potential of anti-Spike-NTD IgA in saliva at predicting persistent smell and taste disorders. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

7. A simulation model for organization and management skills assessment that meets ISO 15189.

Author

Assadi Gazvini, Clara, Coquemont, Cyril, Bluze, Edouard, Vest, Philippe, Coppet, Stéphanie, Honeywood, Yan, and Hejl, Carine

Subjects
ORGANIZATION management, COUGH, SIMULATION methods & models, RAPID diagnostic tests, MEDICAL technologists
Abstract

They are also responsible for ensuring that the samples sent to the laboratory during the test are processed properly and in due time. Keywords: competence; ISO 15189; simulation model EN competence ISO 15189 simulation model e67 e70 4 01/30/23 20230301 NES 230301 To the Editor, In laboratory medicine, quality is fundamental. [Extracted from the article]

Published
2023
Full Text
View/download PDF

8. Carence en fer chez les donneurs de sang en France : état des lieux et perspectives de prévention

Author

Fillet, Anne-Marie, primary, Leclerc, Carole, additional, Martinaud, Christophe, additional, Malard, Lucile, additional, Le Cam, Sophie, additional, Hejl, Carine, additional, Jacquot, Chantal, additional, Woimant, Geneviève, additional, Chueca, Marine, additional, Bésiers, Christophe, additional, Jacquot, Eric, additional, Morel, Pascal, additional, and Richard, Pascale, additional

Published
2021
Full Text
View/download PDF

10. Matériel

Author

Garcia Hejl, Carine, Dedome, Emmanuel, Bugier, Sarah, Vest, Philippe, and Chiane, Denis

Published
2016
Full Text
View/download PDF

12. Iron deficiency among French whole‐blood donors: first assessment and identification of predictive factors

Author

Fillet, Anne‐Marie, primary, Martinaud, Christophe, additional, Malard, Lucile, additional, Le Cam, Sophie, additional, Hejl, Carine, additional, Chenus, Florence, additional, Woimant, Geneviève, additional, Chueca, Marine, additional, Jacquot, Eric, additional, Besiers, Christophe, additional, Morel, Pascal, additional, Djoudi, Rachid, additional, Garrabé, Eliane, additional, and Gross, Sylvie, additional

Published
2020
Full Text
View/download PDF

16. Accreditation of the toxicological screening: recommendations of the SFBC-SFTA group

Author

Guitton, Jérôme, additional, Gaulier, Jean-Michel, additional, Citterio-Quentin, Antony, additional, Abe, Emuri, additional, Allibé, Nathalie, additional, Bartoli, Mireille, additional, Cohen, Sabine, additional, Monteil-Ganiere, Catherine, additional, Garcia-Hejl, Carine, additional, Grosjean, Jérôme, additional, Richard, Damien, additional, Roman, Emilie, additional, Saint-Marcoux, Franck, additional, and Wendremaire, Maeva, additional

Published
2019
Full Text
View/download PDF

17. Iron deficiency among French whole‐blood donors: first assessment and identification of predictive factors.

Author

Fillet, Anne‐Marie, Martinaud, Christophe, Malard, Lucile, Le Cam, Sophie, Hejl, Carine, Chenus, Florence, Woimant, Geneviève, Chueca, Marine, Jacquot, Eric, Besiers, Christophe, Morel, Pascal, Djoudi, Rachid, Garrabé, Eliane, and Gross, Sylvie

Subjects
IRON deficiency, CART algorithms, DECISION trees, LOGISTIC regression analysis, REGRESSION analysis
Abstract

Background: The objectives of this study are to estimate the prevalence of iron deficiency (ID) among French whole‐blood (WB) donors to identify factors associated with ID and to generate decision trees. Study design and methods: A prospective National multicentre study was performed on WB donors from March 11, to April 5th, 2019. Samples were selected randomly to perform serum ferritin. ID was defined as ferritin value under 26 ng/ml. All results were stratified by sex. Factors associated with ID were analysed using multivariate logistic regression model. CART algorithm was used for decision trees. Results: Eleven thousand two hundred fifty eight WB donors were included. ID was more frequent in women (39·5%) than in men (18·0%). Among 7200 repeated donors, women below 50 yo had a higher risk (OR = 2·37; [1·97–2·85] IC95) than those above 50 yo. Factors associated with ID were: haemoglobin level under the threshold at donation n‐1 except for women and n‐2 donation; a low mean corpuscular haemoglobin at n‐1 and n‐2 donations; a shorter interval since n‐1 donation and between n‐1 and n‐2 donations except for women; and women who had given three or four times in the last year. CART algorithm defined high risk of ID subgroups within three populations of donors, new female donors, repeated male donors and repeated female donors. In these identified subgroups, prevalence of ID was up to 72·1%. Conclusions: Our study showed the high prevalence of ID among French WB donors, identified well‐known and new factors associated with ID and defined algorithms predicting ID in three populations. [ABSTRACT FROM AUTHOR]

Published
2021
Full Text
View/download PDF

21. Red Serum and Urine Samples

Author

Garcia Hejl, Carine, primary, Chianea, Denis, primary, Leclerc, Thomas, primary, Plantamura, Julie, primary, and Vest, Philippe, primary

Published
2015
Full Text
View/download PDF

23. Biochimie

Author

Hejl, Carine Garcia, primary, Plantamura, Julie, additional, Chianea, Denis, additional, and Vest, Philippe, additional

Published
2014
Full Text
View/download PDF

25. An Unusual Electrophoresis

Author

Garcia Hejl, Carine, primary, Riviere, Frederic, primary, Sill, Joshua M, primary, Chianea, Denis, primary, and Vest, Philippe, primary

Published
2014
Full Text
View/download PDF

26. Biochimie

Author

Plantamura, Julie, primary, Hejl, Carine Garcia, additional, Chianea, Denis, additional, and Vest, Philippe, additional

Published
2014
Full Text
View/download PDF

27. Pheochromocytoma: Yes or No?

Author

Garcia Hejl, Carine, primary, Dedome, Emmanuel, primary, Chianea, Denis, primary, Ramirez Martinez, Jose, primary, and Vest, Philippe, primary

Published
2014
Full Text
View/download PDF

29. Abstract C129: Relation between long‐term blood pharmacokinetics, pharmacogenomics, and severe neurotoxicity in patients undergoing an oxaliplatin‐based regimen

Author

Bastian, Gérard, primary, Chibaudel, Benoist, additional, Maindrault‐Goebel, Frederique, additional, Garcia‐Hejl, Carine, additional, Bonnetain, Franck, additional, Maillard, Emilie, additional, Rebischung, Christine, additional, Hebbar, Mohamed, additional, André, Thierry, additional, Gil‐Delgado, Marian, additional, Collery, Philippe, additional, Yataghene, Youssef, additional, Maral, Jean, additional, and de Gramont, Aimery, additional

Published
2009
Full Text
View/download PDF

36. Effects of purine nucleosides on the in vitro growth of Cryptosporidium parvum

Author

Lawton, Philippe, Hejl, Carine, Mancassola, Roselyne, Naciri, Muriel, and Petavy, Anne-Françoise

Subjects
*NUCLEOSIDES, *CRYPTOSPORIDIUM parvum, *PURINES
Abstract

The effect of purine nucleosides on the in vitro growth of Cryptosporidium parvum was studied. Culturing the parasite in THP-1 cells for 72 h in growth medium supplemented with adenosine or inosine improved the parasite yields especially in the first 48 h. Similar results were obtained with parasites cultured in Madin–Darby bovine kidney cells and incubated for 24 h with inosine. The addition of inosine to 72-h cultures enhanced the growth of C. parvum in THP-1 cells, especially the trophic stages, whereas the analogue formycin B was toxic to the parasites and induced a marked decrease in the gamont stages. The monitoring of the added purine nucleosides by high performance liquid chromatography showed that at 37°C in the presence of THP-1 cells, a rapid uptake of inosine occurred with hypoxanthine being the main purine present after 2 h in the medium. [Copyright &y& Elsevier]

Published
2003
Full Text
View/download PDF

37. Diagnosis of α1-antitrypsin deficiency using capillary zone electrophoresis.

Author

Hejl, Carine Garcia, Chianea, Denis, Riviere, Frederic, Sill, Joshua, Cuvelier, Isabelle, Renard, Christophe, Plantamura, Julie, and Vest, Philippe

Subjects
*ALPHA 1-antitrypsin, *ALPHA 1-antitrypsin deficiency, *CAPILLARY electrophoresis, *DIAGNOSIS methods, *GLOBULINS
Abstract

The article presents a diagnosis of a1-antitrypsin (AIAT) deficiency using capillary zone electrophoresis on patients prescribed with serum electrophoresis as part of an initial battery of diagnostic laboratory tests. Topics include the parameters within which diagnosis of A1AT was suspected, other causes of low a1-globulin levels on electrophesis such as malnutrition and excessive renal excretion, and why serum electrophoresis is not recommended for diagnosing A1AT deficiency.

Published
2015
Full Text
View/download PDF

38. Validation of an electrothermic atomic absorption spectrometry method for dosage of copper in serum

Author

Garcia Hejl, Carine, Astier, H?l?ne, Servonnet, Aur?lie, and Ramirez, Jos?

Abstract

Objectives: Several severe hereditary human disorders of copper regulatory mechanisms have been identified; they result in copper deficiency (Menkes disease) or in copper overload (Wilson disease). Diagnosis relies on determination of copper in serum and urine. Dosage of copper can be performed by electrothermic atomic absorption spectrometry (EAAS). This article describes how this method has been validated. Method: Protocol used is recommended by the French Pharmaceutical Society (SFSTP). Results: These guidelines allow us to show that this method is accurate and precise and to define its limits of detection and quantification. Conclusion: Dosage of copper in serum has been validated. Objectif?: Un d?s?quilibre du m?tabolisme du cuivre est ? l'origine de maladies g?n?tiques graves?; la maladie de Menk?s lors de d?ficits en cuivre et la maladie de Wilson caract?ris?e par une surcharge en cet oligo-?l?ment. Le diagnostic des ces pathologies implique le dosage du cuivre s?rique et urinaire par spectrom?trie d'absorption atomique ?lectrothermique (SAAE). Nous d?crivons ici le protocole de validation de notre technique de dosage du cuivre s?rique par SAA. M?thode?: Nous avons appliqu? un protocole recommand? par la Soci?t? Fran?aise des Sciences Techniques et Pharmaceutiques (SFSTP). R?sultats?: Ce protocole nous a permis de tester la lin?arit?, la fid?lit? et l'exactitude de notre m?thode et de d?finir le domaine de lin?arit? ainsi que les limites de d?tection et de quantification. Conclusion?: L'?tude r?alis?e a permis de valider la m?thode de dosage utilis?e au laboratoire.

Published
2009

39. Use of a non‐adherent cell culture system for testing the effect of 2′,3′‐dideoxyinosine against Cryptosporidium parvum

Author

Lawton, Philippe, Hejl, Carine, Sarciron, Marie‐Elisabeth, Mancassola, Roselyne, Naciri, Muriel, and Petavy, Anne‐Françoise

Abstract

The in vitro cultivation of Cryptosporidium parvumin the non‐adherent cell line THP‐1 was evaluated for its capability as a useful additional model to investigate the effect of drugs on this parasite. The purine analog antiviral 2′,3′‐dideoxyinosine (ddI) was evaluated and compared to the reference molecule paromomycin in sequential 24 hour experiments beginning at 24 and 72 hour post‐infection. The ability of this technique to evaluate the various parasite stages showed that ddI displayed a dose‐dependent efficacy especially on the trophozoite and sexual stages. Paromomycin displayed a lower efficacy than previously reported. Both drugs induced a decrease in the number of multiparasitized cells. These results indicate that the purine salvage pathway should be a key chemotherapeutic target against C. parvum.

Published
1999
Full Text
View/download PDF

43. Groupe de travail SFBC « Marqueurs biochimiques de COVID-19 »

Author

Marie-Christine, Beauvieux, Annie M, Bérard, Isabelle, Aimone-Gastin, Françoise, Barbé, Yann, Barguil, Delphine, Collin-Chavagnac, Hervé, Delacour, Céline, Delevallée, Valérie, Nivet-Antoine, Katell, Peoc'h, Carole, Poupon, François, Schmitt, Laurence, Piéroni, Vincent, Sapin, Charlotte, Oris, CarMeN, laboratoire, CHU Bordeaux [Bordeaux], Centre de résonance magnétique des systèmes biologiques (CRMSB), Université de Bordeaux (UB)-Centre National de la Recherche Scientifique (CNRS), Université de Bordeaux (UB), Nutrition-Génétique et Exposition aux Risques Environnementaux (NGERE), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Lorraine (UL), Centre Hospitalier Régional Universitaire de Nancy (CHRU Nancy), Centre hospitalier territorial Gaston-Bourret [Nouméa], Centre Hospitalier Lyon Sud [CHU - HCL] (CHLS), Hospices Civils de Lyon (HCL), Hôpital d'Instruction des Armées Begin, Service de Santé des Armées, Gen-Bio [Clermont-Ferrand] (Groupe Inovie ), Innovations thérapeutiques en hémostase (IThEM - U1140), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Paris Cité (UPCité), CHU Necker - Enfants Malades [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Hôpital Beaujon, AP-HP - Hôpital Bichat - Claude Bernard [Paris], Centre Hospitalier de Gonesse (CHU Gonesse), Groupe Hospitalier Bretagne Sud (GHBS), CHU Tenon [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), CHU Montpellier, Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier), Génétique, Reproduction et Développement (GReD), Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)-Université Clermont Auvergne (UCA), Membres du Groupe de travail SFBC « Marqueurs biochimiques de COVID-19 » Aimone-Gastin Isabelle, Alcaraz Stéphanie, Allouche Stéphane, Balduyck Malika, Barbé Franc¸oise, Barguil Yann, Bastard Jean-Philippe, Beaudeux Jean-Louis, Beauvieux Marie-Christine, Ben Lassoued Amin, Benz de Bretagne Isabelle, Bérard Annie, Bermont Laurent, Bigot-Corbel Edith, Bost Muriel, Bourbonneux Valery, Brunel Valery, Carré Jean-Luc, Chenevier-Gobeaux Camille, Chevrier Marc, Chinetti Giulia, Collin-Chavagnac Delphine, Delacour Hervé, Delevallée Delphine, Desroys du Roure Franc¸ois, Faure Patrice, Galhaud Jean-Philippe, Galinier Anne, Hauet Thierry, Hejl Carine, Jolly Emilie, Kamel Said, Lehmann Sylvain, Leroy Aline, Lessinger Jean-Marc, Levy Pacifique, LorecPenet Anne-Marie, Mesli Samir, Monnet Dagui, Moreau Caroline, Mouly Laurence, Nivet-Antoine Valérie, Oueidat Nathalie, Pecquet Mathieu, Peoc’h Katell, Piéroni Laurence, Poupon Carole, Roubille Martine, Rucheton Benoit, Sakka Medhi, Sapin Vincent, Saunier Vincent, Scherrer Florian, Schmitt Franc¸ois, Zaepfel Sabine, Zozor Samuel Liste des correspondants en biochimie Sous-groupe Privés Boulier Alexandre (Saint-Thibery), Saint Martin Chloé (Saint-Flour), Chatelain Rémi (Roanne), Deleglise Guillaume (Clermont-Ferrand), Froment Pauline (Ganges), Paulus Jean-Marcel (Nancy), Merah Kader (Saint-Denis), Sevin Eric (Limoges), Barrand Lionel (Strasbourg), Boetsch Morgane (Colmar), Lautier Carine (Montpellier), Charrier Frédéric (Arles), Magraff Stéphane (Brumath) Sous-groupe Outre-Mer (OM)/francophonie Cavalier Etienne (CHU Liège), Demar Magali (CH Cayenne), de Guire Vincent et Wang Han Ting (Montréal), Laso Bautista Javier (HFE Cerdagne), Dumas-Chastang Elsa (Papeete, ILM), Outreville Jonathan (Papeete, CHT Mamao), Tayeb Nicole (CH Mayotte), Monde Absalome (CHU Treichville Abidjan), Chiaradia Laura (CH Nouméa), Alomar Yves (CH de St Pierre & Miquelon), Devaud Francois (CH d’Uturoa), Diallo Agne Fatou, Kandji Pape Matar, Gueye Papa Madieye (CHU Fann, Sénégal), Temmar Abdelhakim (CHU de Guadeloupe), Sakandé Jean et Kabré Elie (CHU Yalgado Uuedraogo, Burkina Faso), Padelli Maël (CHU de Martinique), Chabraoui Layachi, pour la Fédération Internationale Francophone de Biologie et Médecine de Laboratoire (FIFBCML), Magny Eric (CHU Réunion) Sous-groupe CH Got Laurence et Francia Thomas (Orléans), Tournoys Marie-Hélène (Béthune), Morvan Cécile (Villefranche), Kadi Habiba (Gonesse), Balluet Rémi (Bourg-en-Bresse), Fissor-Magdelein Cristel (Monaco) Sous-groupe Hôpitaux d’instruction des armées (HIA) Vest Philippe (Clamart), Plantamura Julie (Toulon) Sous-groupe CHU Nord-Est Salignac Sylvain (Nancy), Maboudou Patrice et Onraed Brigitte (Lille), Schneider Nathalie et Szymezak Jean (Reims), Alemann Mathieu, Glady Ludovic, Lavaux Thomas, Kemmel Véronique, Lefevre Paul et Bayer Sophie (Strasbourg), Billoir Paul et Gueudin Marie (Rouen), Grandhomme Frédérique et Gondolf Clémentine (Caen) Sous-groupe CHU Ouest Moal Valérie et Larcher- Joubaud Franc¸oise (Angers), Guery Eve-Anne (Tours), Lefevre Charles, Collet Nicolas et Peltier Lucas (Rennes), Lacape Geneviève, Redonnet-Vernhet Isabelle, Richard Emmanuel et Gilleron Véronique (Bordeaux) Sous-groupe CHU Assistance publique-Hôpitaux de Paris (AP-HP) Czerkiewicz Isabelle (Henri Mondor), Vicca Stéphanie (Necker), Manceau Hanna (Beaujon), Boutten Anne (Bichat) Sous-groupe CHU Sud Ausseil Jérôme (Toulouse), Hamoir Maria, Zemori Laurence, Deconde-Lebutor Célia (Nice), Lamy Anaïs (Nîmes) Sous-groupe CHU Auvergne Rhône-Alpes-Bourgogne Franche-Comté (ARA-BFC) Gambert Ségolène (Dijon), Gonzalo Philippe (Saint-Etienne), Cartier Régine (Lyon), and Oris Charlotte (ClermontFerrand)

Subjects
030213 general clinical medicine, History, [SDV]Life Sciences [q-bio], Disease, France/epidemiology, Biochemistry, Community Networks, Disease Outbreaks, Viral/blood/*diagnosis/epidemiology, 0302 clinical medicine, Health care, Pandemic, Videoconferencing/organization & administration/standards, Intersectoral Collaboration, medical biology, Professional Practice, General Medicine, Clinical Laboratory Services, biological markers, 21st Century, 3. Good health, [SDV] Life Sciences [q-bio], France, Coronavirus Infections, Biomarkers/*analysis/blood, Societies, Scientific, medicine.medical_specialty, Coronavirus disease 2019 (COVID-19), Pneumonia, Viral, Biochemistry/*organization & administration/standards, History, 21st Century, Scientific/*organization & administration/standards, 03 medical and health sciences, Betacoronavirus, Community Networks/organization & administration/standards/trends, medicine, Clinical Laboratory Services/*organization & administration/standards, Humans, Betacoronavirus/isolation & purification/pathogenicity, Medical prescription, China, Pandemics, Professional Practice/organization & administration/standards/trends, business.industry, SARS-CoV-2, COVID-19, Pneumonia, Private sector, Family medicine, covid-19, Coronavirus Infections/blood/*diagnosis/epidemiology, Videoconferencing, business, Societies, Biomarkers
Abstract

The SARS-CoV-2 virus is responsible for an epidemic disease called COVID-19, which was initially evidenced in Wuhan, China, and spread very rapidly in China and around the world. In France, the first isolated case seems now to be reported in December 2019, stage 3 of the COVID-19 epidemic was triggered on March 14(th), the start of the planned containment exit from May 11(th). Healthcare services have faced a large influx of patients who may be beyond their capacity to receive and care, particularly in the Large-East and Ile-de-France regions. Some patients show an evolution of the disease never observed before with other coronaviruses and develop in a few days a very important inflammatory reaction, which can lead to death of patients. A working group of the French Society of Clinical Biology (SFBC) was set up with the objective of providing updated information on the current status of the biological prescriptions (focusing on biochemistry ones) and their evolution during the epidemic, and of analyzing the biological parameters associated with comorbidities and patient evolution in order to link biological results with medical events. The expanded working group covers all sectors of medical biology in France and extends to the French-speaking world: hospital sectors (CHU and CH, Army Training Hospitals) and the private sector opening a field of view on the biological situation in establishments for dependent elderly, social establishments and clinical medical institutions. The purpose of this article is the presentation of this working group and its immediate and future actions., Le virus SARS-CoV-2 est responsable d’une maladie épidémique dénommée COVID-19 initialement mise en évidence à Wuhan (Chine) et qui s’est propagée très rapidement en Chine puis dans le monde entier. En France, le premier cas isolé semble être signalé dès la fin du mois de décembre2019, le stade 3 de l’épidémie a été déclenché le 14 mars 2020 et la sortie progressive du confinement est prévue à partir du 11 mai 2020. Les services de soins ont fait face à un afflux massif de patients pouvant déborder leurs capacités d’accueil et de prise en charge, notamment dans les régions Grand-Est et Ile-de-France. Certains patients présentent une évolution de la maladie encore jamais observée avec les coronavirus et développent en quelques jours une réaction inflammatoire très importante, pouvant mener au décès. Un groupe de travail de la Société française de biologie clinique (SFBC) s’est constitué, ayant pour objectif de faire le point sur les prescriptions biologiques et leur évolution au cours de l’épidémie, d’analyser les paramètres biologiques, avec un focus biochimique, associés aux comorbidités et à l’évolution du patient, dans le but de relier les résultats biologiques avec des évènements du parcours de soins du patient. Ce groupe de travail recouvre tous les secteurs publics (CHU, CH, Hôpitaux d’instruction des armées) et privés de la biologie médicale en France métropolitaine et ultra-marine ; il s’étend également à la francophonie. Il permet une vision large sur la situation biologique en milieu hospitalier, établissements d’hébergements de personnes âgées dépendantes (Ehpad), établissements médicaux sociaux (EMS) et en cliniques. Le but de cet article est la présentation de ce groupe de travail et ses actions immédiates et à venir.

Published
2020
Full Text
View/download PDF

44. Groupe de travail SFBC « Marqueurs biochimiques de COVID-19 »

Author

Beauvieux, M. C., Bérard, A. M., Aimone-Gastin, I., Barbe, F., Barguil, Y., Collin-Chavagnac, D., Delacour, H., Delevallee, C., Nivet-Antoine, V., Peoc'H, K., Poupon, C., Schmitt, F., Piéroni, L., Sapin, V., CHU Bordeaux [Bordeaux], Centre de résonance magnétique des systèmes biologiques (CRMSB), Université de Bordeaux (UB)-Centre National de la Recherche Scientifique (CNRS), Université de Bordeaux (UB), Nutrition-Génétique et Exposition aux Risques Environnementaux (NGERE), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Lorraine (UL), Centre Hospitalier Régional Universitaire de Nancy (CHRU Nancy), Centre hospitalier territorial Gaston-Bourret [Nouméa], Centre Hospitalier Lyon Sud [CHU - HCL] (CHLS), Hospices Civils de Lyon (HCL), Hôpital d'Instruction des Armées Begin, Service de Santé des Armées, Gen-Bio [Clermont-Ferrand] (Groupe Inovie ), Innovations thérapeutiques en hémostase = Innovative Therapies in Haemostasis (IThEM - U1140), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Paris Cité (UPCité), CHU Necker - Enfants Malades [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Hôpital Beaujon, AP-HP - Hôpital Bichat - Claude Bernard [Paris], Centre Hospitalier de Gonesse (CHU Gonesse), Groupe Hospitalier Bretagne Sud (GHBS), CHU Tenon [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), CHU Montpellier, Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier), Génétique, Reproduction et Développement (GReD), Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)-Université Clermont Auvergne (UCA), Membres du Groupe de travail SFBC « Marqueurs biochimiques de COVID-19 » Aimone-Gastin Isabelle, Alcaraz Stéphanie, Allouche Stéphane, Balduyck Malika, Barbé Franc¸oise, Barguil Yann, Bastard Jean-Philippe, Beaudeux Jean-Louis, Beauvieux Marie-Christine, Ben Lassoued Amin, Benz de Bretagne Isabelle, Bérard Annie, Bermont Laurent, Bigot-Corbel Edith, Bost Muriel, Bourbonneux Valery, Brunel Valery, Carré Jean-Luc, Chenevier-Gobeaux Camille, Chevrier Marc, Chinetti Giulia, Collin-Chavagnac Delphine, Delacour Hervé, Delevallée Delphine, Desroys du Roure Franc¸ois, Faure Patrice, Galhaud Jean-Philippe, Galinier Anne, Hauet Thierry, Hejl Carine, Jolly Emilie, Kamel Said, Lehmann Sylvain, Leroy Aline, Lessinger Jean-Marc, Levy Pacifique, LorecPenet Anne-Marie, Mesli Samir, Monnet Dagui, Moreau Caroline, Mouly Laurence, Nivet-Antoine Valérie, Oueidat Nathalie, Pecquet Mathieu, Peoc’h Katell, Piéroni Laurence, Poupon Carole, Roubille Martine, Rucheton Benoit, Sakka Medhi, Sapin Vincent, Saunier Vincent, Scherrer Florian, Schmitt Franc¸ois, Zaepfel Sabine, Zozor Samuel Liste des correspondants en biochimie Sous-groupe Privés Boulier Alexandre (Saint-Thibery), Saint Martin Chloé (Saint-Flour), Chatelain Rémi (Roanne), Deleglise Guillaume (Clermont-Ferrand), Froment Pauline (Ganges), Paulus Jean-Marcel (Nancy), Merah Kader (Saint-Denis), Sevin Eric (Limoges), Barrand Lionel (Strasbourg), Boetsch Morgane (Colmar), Lautier Carine (Montpellier), Charrier Frédéric (Arles), Magraff Stéphane (Brumath) Sous-groupe Outre-Mer (OM)/francophonie Cavalier Etienne (CHU Liège), Demar Magali (CH Cayenne), de Guire Vincent et Wang Han Ting (Montréal), Laso Bautista Javier (HFE Cerdagne), Dumas-Chastang Elsa (Papeete, ILM), Outreville Jonathan (Papeete, CHT Mamao), Tayeb Nicole (CH Mayotte), Monde Absalome (CHU Treichville Abidjan), Chiaradia Laura (CH Nouméa), Alomar Yves (CH de St Pierre & Miquelon), Devaud Francois (CH d’Uturoa), Diallo Agne Fatou, Kandji Pape Matar, Gueye Papa Madieye (CHU Fann, Sénégal), Temmar Abdelhakim (CHU de Guadeloupe), Sakandé Jean et Kabré Elie (CHU Yalgado Uuedraogo, Burkina Faso), Padelli Maël (CHU de Martinique), Chabraoui Layachi, pour la Fédération Internationale Francophone de Biologie et Médecine de Laboratoire (FIFBCML), Magny Eric (CHU Réunion) Sous-groupe CH Got Laurence et Francia Thomas (Orléans), Tournoys Marie-Hélène (Béthune), Morvan Cécile (Villefranche), Kadi Habiba (Gonesse), Balluet Rémi (Bourg-en-Bresse), Fissor-Magdelein Cristel (Monaco) Sous-groupe Hôpitaux d’instruction des armées (HIA) Vest Philippe (Clamart), Plantamura Julie (Toulon) Sous-groupe CHU Nord-Est Salignac Sylvain (Nancy), Maboudou Patrice et Onraed Brigitte (Lille), Schneider Nathalie et Szymezak Jean (Reims), Alemann Mathieu, Glady Ludovic, Lavaux Thomas, Kemmel Véronique, Lefevre Paul et Bayer Sophie (Strasbourg), Billoir Paul et Gueudin Marie (Rouen), Grandhomme Frédérique et Gondolf Clémentine (Caen) Sous-groupe CHU Ouest Moal Valérie et Larcher- Joubaud Franc¸oise (Angers), Guery Eve-Anne (Tours), Lefevre Charles, Collet Nicolas et Peltier Lucas (Rennes), Lacape Geneviève, Redonnet-Vernhet Isabelle, Richard Emmanuel et Gilleron Véronique (Bordeaux) Sous-groupe CHU Assistance publique-Hôpitaux de Paris (AP-HP) Czerkiewicz Isabelle (Henri Mondor), Vicca Stéphanie (Necker), Manceau Hanna (Beaujon), Boutten Anne (Bichat) Sous-groupe CHU Sud Ausseil Jérôme (Toulouse), Hamoir Maria, Zemori Laurence, Deconde-Lebutor Célia (Nice), Lamy Anaïs (Nîmes) Sous-groupe CHU Auvergne Rhône-Alpes-Bourgogne Franche-Comté (ARA-BFC) Gambert Ségolène (Dijon), Gonzalo Philippe (Saint-Etienne), Cartier Régine (Lyon), Oris Charlotte (ClermontFerrand), Centre National de la Recherche Scientifique (CNRS)-Université de Bordeaux (UB), Innovations thérapeutiques en hémostase (IThEM - U1140), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Paris (UP), and Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)

Subjects
History, Professional Practice/organization & administration/standards/trends, SARS-CoV-2, [SDV]Life Sciences [q-bio], Biochemistry/*organization & administration/standards, medical biology, Pneumonia, France/epidemiology, biological markers, 21st Century, Disease Outbreaks, Scientific/*organization & administration/standards, Viral/blood/*diagnosis/epidemiology, covid-19, Community Networks/organization & administration/standards/trends, Coronavirus Infections/blood/*diagnosis/epidemiology, Videoconferencing/organization & administration/standards, Clinical Laboratory Services/*organization & administration/standards, Humans, Betacoronavirus/isolation & purification/pathogenicity, Covid-19, Societies, Pandemics, Biomarkers/*analysis/blood, Intersectoral Collaboration
Abstract

International audience; The SARS-CoV-2 virus is responsible for an epidemic disease called COVID-19, which was initially evidenced in Wuhan, China, and spread very rapidly in China and around the world. In France, the first isolated case seems now to be reported in December 2019, stage 3 of the COVID-19 epidemic was triggered on March 14(th), the start of the planned containment exit from May 11(th). Healthcare services have faced a large influx of patients who may be beyond their capacity to receive and care, particularly in the Large-East and Ile-de-France regions. Some patients show an evolution of the disease never observed before with other coronaviruses and develop in a few days a very important inflammatory reaction, which can lead to death of patients. A working group of the French Society of Clinical Biology (SFBC) was set up with the objective of providing updated information on the current status of the biological prescriptions (focusing on biochemistry ones) and their evolution during the epidemic, and of analyzing the biological parameters associated with comorbidities and patient evolution in order to link biological results with medical events. The expanded working group covers all sectors of medical biology in France and extends to the French-speaking world: hospital sectors (CHU and CH, Army Training Hospitals) and the private sector opening a field of view on the biological situation in establishments for dependent elderly, social establishments and clinical medical institutions. The purpose of this article is the presentation of this working group and its immediate and future actions.; Le virus SARS-CoV-2 est responsable d’une maladie épidémique dénommée COVID-19 initialement mise en évidence à Wuhan (Chine) et qui s’est propagée très rapidement en Chine puis dans le monde entier. En France, le premier cas isolé semble être signalé dès la fin du mois de décembre2019, le stade 3 de l’épidémie a été déclenché le 14 mars 2020 et la sortie progressive du confinement est prévue à partir du 11 mai 2020. Les services de soins ont fait face à un afflux massif de patients pouvant déborder leurs capacités d’accueil et de prise en charge, notamment dans les régions Grand-Est et Ile-de-France. Certains patients présentent une évolution de la maladie encore jamais observée avec les coronavirus et développent en quelques jours une réaction inflammatoire très importante, pouvant mener au décès. Un groupe de travail de la Société française de biologie clinique (SFBC) s’est constitué, ayant pour objectif de faire le point sur les prescriptions biologiques et leur évolution au cours de l’épidémie, d’analyser les paramètres biologiques, avec un focus biochimique, associés aux comorbidités et à l’évolution du patient, dans le but de relier les résultats biologiques avec des évènements du parcours de soins du patient. Ce groupe de travail recouvre tous les secteurs publics (CHU, CH, Hôpitaux d’instruction des armées) et privés de la biologie médicale en France métropolitaine et ultra-marine ; il s’étend également à la francophonie. Il permet une vision large sur la situation biologique en milieu hospitalier, établissements d’hébergements de personnes âgées dépendantes (Ehpad), établissements médicaux sociaux (EMS) et en cliniques. Le but de cet article est la présentation de ce groupe de travail et ses actions immédiates et à venir.

Published
2020
Full Text
View/download PDF

45. Working towards accreditation by the International Standards Organization 15189 Standard: how to validate an in-house developed method an example of lead determination in whole blood by electrothermal atomic absorption spectrometry.

Author

Garcia Hejl C, Ramirez JM, Vest P, Chianea D, and Renard C

Subjects
Accreditation, Humans, Laboratories standards, Lead standards, Reference Standards, Lead blood, Spectrophotometry, Atomic standards, Validation Studies as Topic
Abstract

Laboratories working towards accreditation by the International Standards Organization (ISO) 15189 standard are required to demonstrate the validity of their analytical methods. The different guidelines set by various accreditation organizations make it difficult to provide objective evidence that an in-house method is fit for the intended purpose. Besides, the required performance characteristics tests and acceptance criteria are not always detailed. The laboratory must choose the most suitable validation protocol and set the acceptance criteria. Therefore, we propose a validation protocol to evaluate the performance of an in-house method. As an example, we validated the process for the detection and quantification of lead in whole blood by electrothermal absorption spectrometry. The fundamental parameters tested were, selectivity, calibration model, precision, accuracy (and uncertainty of measurement), contamination, stability of the sample, reference interval, and analytical interference. We have developed a protocol that has been applied successfully to quantify lead in whole blood by electrothermal atomic absorption spectrometry (ETAAS). In particular, our method is selective, linear, accurate, and precise, making it suitable for use in routine diagnostics.

Published
2014
Full Text
View/download PDF

46. [Disseminated intravascular coagulation in solid tumours].

Author

Ferrand FR, Garcia-Hejl C, Moussaid Y, Schernberg A, Bidard FC, Pavic M, Khenifer S, and Stoclin A

Subjects
Anticoagulants therapeutic use, Blood Coagulation physiology, Coagulants therapeutic use, Factor VIIa therapeutic use, Humans, Neoplasms pathology, Neoplasms therapy, Platelet Transfusion, Prognosis, Recombinant Proteins therapeutic use, Risk Factors, Disseminated Intravascular Coagulation blood, Disseminated Intravascular Coagulation diagnosis, Disseminated Intravascular Coagulation epidemiology, Disseminated Intravascular Coagulation etiology, Disseminated Intravascular Coagulation physiopathology, Disseminated Intravascular Coagulation therapy, Neoplasms blood, Paraneoplastic Syndromes blood, Paraneoplastic Syndromes diagnosis, Paraneoplastic Syndromes etiology, Paraneoplastic Syndromes physiopathology, Paraneoplastic Syndromes therapy
Abstract

Disseminated intravascular coagulation (DIC) is a complex abnormality of hemostasis with dramatic consequences and long described as associated with tumors. Yet the diagnosis and management of paraneoplastic DIC are poorly defined. The purpose of this paper is to review DIC associated with solid tumors, at the pathophysiological and therapeutic levels in particular. We also report data from a recent retrospective series of patients with DIC in the context of a solid tumor, to illustrate the epidemiological, clinical and prognostic.

Published
2014
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results